scispace - formally typeset
Open AccessJournal ArticleDOI

Loss of Metabolic Flexibility in the Failing Heart.

TLDR
An increasing body of evidence shows that increasing cardiac ATP production and/or modulating cardiac energy substrate preference positively correlates with heart function and can lead to better outcomes.
Abstract
To maintain its high energy demand the heart is equipped with a highly complex and efficient enzymatic machinery that orchestrates ATP production using multiple energy substrates, namely fatty acids, carbohydrates (glucose and lactate), ketones and amino acids. The contribution of these individual substrates to ATP production can dramatically change, depending on such variables as substrate availability, hormonal status and energy demand. This "metabolic flexibility" is a remarkable virtue of the heart, which allows utilization of different energy substrates at different rates to maintain contractile function. In heart failure, cardiac function is reduced, which is accompanied by discernible energy metabolism perturbations and impaired metabolic flexibility. While it is generally agreed that overall mitochondrial ATP production is impaired in the failing heart, there is less consensus as to what actual switches in energy substrate preference occur. The failing heart shift toward a greater reliance on glycolysis and ketone body oxidation as a source of energy, with a decrease in the contribution of glucose oxidation to mitochondrial oxidative metabolism. The heart also becomes insulin resistant. However, there is less consensus as to what happens to fatty acid oxidation in heart failure. While it is generally believed that fatty acid oxidation decreases, a number of clinical and experimental studies suggest that fatty acid oxidation is either not changed or is increased in heart failure. Of importance, is that any metabolic shift that does occur has the potential to aggravate cardiac dysfunction and the progression of the heart failure. An increasing body of evidence shows that increasing cardiac ATP production and/or modulating cardiac energy substrate preference positively correlates with heart function and can lead to better outcomes. This includes increasing glucose and ketone oxidation and decreasing fatty acid oxidation. In this review we present the physiology of the energy metabolism pathways in the heart and the changes that occur in these pathways in heart failure. We also look at the interventions which are aimed at manipulating the myocardial metabolic pathways toward more efficient substrate utilization which will eventually improve cardiac performance.

read more

Citations
More filters
Journal ArticleDOI

Heart Failure in Type 2 Diabetes Mellitus.

TL;DR: The state of knowledge about the impact of existing antihyperglycemic therapies on HF is summarized, potential mechanisms for beneficial or deleterious effects are discussed, and currently approved pharmacological therapies for HF are reviewed.
Journal ArticleDOI

Cardiac Energy Metabolism in Heart Failure

TL;DR: In this paper, the effects of metabolic changes that occur in heart failure are complex and are dependent not only on the severity and type of heart failure present but also on the co-existence of common comorbidities such as obesity and type 2 diabetes.
Journal ArticleDOI

Cellular and molecular pathobiology of heart failure with preserved ejection fraction.

TL;DR: A review of the cellular and molecular pathobiology of heart failure with preserved ejection fraction (HFpEF) can be found in this paper, with the major focus being on mechanisms relevant to the heart.
Journal ArticleDOI

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure

TL;DR: Recent findings of cardiac metabolic changes in response to hemodynamic stress and cardiac ischemia with a focus on glucose utilization are reviewed and potential therapeutic targets from carbohydrate metabolic pathways to tackle this devastating heart disease are discussed.
References
More filters
Journal ArticleDOI

Randomized controlled trial.

Journal ArticleDOI

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI

The failing heart--an engine out of fuel.

TL;DR: This review describes cardiac energy metabolism, appraises the methods used for its assessment, evaluates the role of impaired energy metabolism in heart failure, and gives options for metabolic therapy.
Related Papers (5)
Trending Questions (1)
What causes the loss of flexibility?

The loss of metabolic flexibility in the failing heart is caused by discernible energy metabolism perturbations and impaired metabolic flexibility.